Personalis Inc (PSNL)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug...

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery...

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection Personalis, Inc. (Nasdaq: PSNL), a leader...

Form 8-K - Current report

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Expanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor...

Personalis to Participate in Upcoming Investor Events

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be...

Form 8-K - Current report

Form 8-K - Current report

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Expanded coverage, supported by published data from the Vall d’Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Personalis Reports First Quarter Results and Recent Highlights

Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 Medicare coverage secured for lung cancer surveillance...